Journal article
Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease A Systematic Review and Meta-analysis
J Martinkova, FC Quevenco, H Karcher, A Ferrari, E Charlotte Sandset, C Szoeke, J Hort, R Schmidt, A Santuccione Chadha, M Teresa Ferretti
JAMA Network Open | Published : 2021
Abstract
IMPORTANCE Women represent two-thirds of patients with Alzheimer disease (AD), and sex differences might affect results of randomized clinical trials (RCTs). However, little information exists on differences in sex as reported in RCTs for AD. OBJECTIVE To assess the ratio of females to males and the reporting of sex-stratified data in large pharmaceutical RCTs for AD. DATA SOURCES A search for pharmaceutical RCTs for AD was conducted on September 4, 2019, using ClinicalTrials.gov with the key word Alzheimer disease, and articles related to those trials were identified using the PubMed, Scopus, and Google Scholar databases. Searches were conducted between September 4 and October 31, 2019, and..
View full abstractRelated Projects (2)
Grants
Awarded by Alzheimer's Association
Funding Acknowledgements
Dr Martinkova was supported by project 436119 of the Charles University Grant Agency, Second Faculty of Medicine, and by the Avast Foundation (Nadacni fond Avast) together with the Czech Alzheimer's Foundation (Alzheimer nadacni fond). Dr Szoeke was supported by grants 547500, 1032350, and 1062133 from the National Health and Medical Research Council, Australia, and grant NIA320312 from the Alzheimer's Association.